Invokana Efficacy

Blood drop
 

Invokana Efficacy

Glycaemic Efficacy

Invokana eliminates more blood glucose every day than any other SGLT2i1-5

This is not a head-to-head study; results from phase 1 studies of urinary glucose excretion in patients with type 2 diabetes.1-5

A bar graph showing average urinary glucose excretion

Invokana gets more patients to HbA1c target than any other SGLT2i as add-on to metformin

In patients tolerating Invokana 100 mg who have an eGFR ≥60 mL/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 300 mg.1

This is not a head-to-head study; figures are taken from respective SmPCs.1-4

A bar graph showing clinical effectiveness of SGLT2 inhibitors
58% of patients given Invokana 300 mg in addition to metformin achieve the 7% HbA1c target1

Invokana is more effective at reducing HbA1c and weight than some other oral
T2DM treatments

Head-to-head studies are not available for all drug combinations; network meta-analyses (NMA) allow indirect treatment comparisons to be made.

Methodology: In an independent NMA using a frequentist model, pairwise random-effects were performed to estimate study variance. The aim of this NMA, which reviewed 38 trials involving 23,997 patients, was to assess the comparative safety and efficacy of SGLT2 inhibitors in treating hyperglycaemia in adults with T2DM. Data was not available for ertugliflozin at the time of analysis.6

A bar graph showing reduction in HbA1c and weight compared to metmorfin, DPP4 inhibitors
Abbreviations

DPP4 inhibitors: Dipeptidyl Peptidase-4 inhibitors; eGFR: estimated Glomerular Filtration Rate; HbA1c: Haemoglobin A1c; NMA: Network Meta-Analyses; SmPC: Summary of Product Characteristics; SGLT2i: Sodium-Glucose Co-transporter 2 inhibitor; T2DM: Type 2 Diabetes Mellitus.

References
  • 1. Invokana Summary of Product Characteristics. Napp Pharmaceuticals Limited. Available at: https://www.medicines.org.uk/emc/product/8855/smpc and
    https://www.medicines.org.uk/emc/product/12057/smpc [Accessed May 2021].
  • 2. Dapagliflozin Summary of Product Characteristics. AstraZeneca. Available at: https://www.medicines.org.uk/emc/product/7607 [Accessed May 2021].
  • 3. Empagliflozin Summary of Product Characteristics. Boehringer Ingelheim. Available at: https://www.medicines.org.uk/emc/product/5441 [Accessed May 2021].
  • 4. Ertugliflozin Summary of Product Characteristics. Merck Sharp & Dohme. Available at: https://www.medicines.org.uk/emc/product/9803 [Accessed May 2021].
  • 5. Sahasrabudhe V, Terra S, Hickman A, et al. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus. J Clin Pharm. 2017;57(11):1432-1443. doi:10.1002/jcph.955.
  • 6. Zaccardi F, Webb D, Htike Z, et al. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, Obesity and Metabolism. 2016;18(8):783-794. doi:10.1111/dom.12670.
Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.